Company: HFFG
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001680873-25-000057
Chunk: 12

Company: HF Foods Group Inc.
Filing Date: 2025-09-25
Form: 424B5
Chunk 12
---
     | $ |      | 1.70 |
| Dilution per share to investors purchasing shares in this offering         |     |   |      |      |     | $ |      | 1.69 |

An increase of $0.25 per share in the price at which the shares are sold from the assumed offering price of $3.39 per share shown in the table above, assuming that all of our common stock in the aggregate amount of $100,000,000 during the term of the Sales Agreement with the Sales Agents is sold at that price, would increase our as adjusted net tangible book value per share to $1.75 and would increase the dilution in net tangible book value per share to new investors in this offering to $1.89, after deducting commissions and estimated offering expenses payable by us. A decrease of $0.25 per share in the price at which the shares are sold from the assumed offering price of $3.39 per share shown in the table above, assuming all of our common stock in the aggregate amount of $100,000,000 during the term of the Sales Agreement with the Sales Agents is sold at that price, would decrease our as adjusted net tangible book value per share to $1.66 and would decrease the dilution in net tangible book value per share to new investors in this offering to $1.48, after deducting commissions and estimated offering expenses payable by us.

The number of shares of common stock to be outstanding is based on 53,014,705 shares of common stock outstanding as of June 30, 2025, and excludes:

• 671,128 shares of our common stock issuable upon vesting of outstanding time-based restricted stock units;

• 1,077,464 shares of our common stock issuable upon vesting of outstanding performance-based restricted stock units; and

• 3,765,214 shares of our common stock reserved for future issuance under the HF Foods Group Inc. 2018 Omnibus Equity Incentive Plan.

Except as otherwise indicated, all information in this prospectus supplement and the accompanying prospectus assumes no exercise of the outstanding options or warrants referred to above, no vesting and settlement of the outstanding restricted stock units referred to above, and no sales pursuant to the Sales Agreement other than this offering.

<div align='center'>S-9</div>

83092273

In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our